Abstract
Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have